Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation

Open Access 20-04-2024 | Sarcopenia | Original Article

Sarcopenic obesity and reduced BMD in young men living with HIV: body composition and sex steroids interplay

Authors: S. De Vincentis, C. Greco, F. Fanelli, M. C. Decaroli, C. Diazzi, M. Mezzullo, J. Milic, M. C. De Santis, L. Roli, U. Pagotto, G. Guaraldi, V. Rochira

Published in: Journal of Endocrinological Investigation

Login to get access

Abstract

Purpose

Sex steroids play a key role on male bone homeostasis and body composition (BC), their role in men living with HIV (MLWH) is less recognized. This study aimed at investigating the prevalence of low BMD, sarcopenia, and sarcopenic obesity (SO) and their relationship with sex steroids in MLWH aged < 50.

Methods

Prospective, cross-sectional, observational study on MLWH younger than 50 (median age 47.0 years). BC and BMD were evaluated with DXA. Two different definitions of sarcopenia were applied: appendicular lean mass/height2 (ALMI) < 7.26 kg/m2 or appendicular lean mass/body weight (ALM/W) < 28.27%. Low BMD was defined for Z-score < −2.0. Sarcopenia coupled with obesity identified SO. Serum total testosterone (T) and estradiol (E2) were measured by LC–MS/MS; free testosterone (cFT) was calculated by Vermeulen equation.

Results

Sarcopenia was detected in 107 (34.9%) and 44 (14.3%) out of 307 MLWH according to ALMI and ALM/W, respectively. The prevalence of SO was similar by using both ALMI (11.4%) and ALM/W (12.4%). Sarcopenic and SO MLWH had lower total T and cFT in both the definition for sarcopenia. BMD was reduced in 43/307 (14.0%). Serum E2 < 18 pg/mL was an independent contributing factor for sarcopenia, SO, and low BMD.

Conclusions

T and E2 are important determinants of BC even in MLWH. This is among the first studies investigating the distribution of obesity phenotypes and the prevalence of SO among MLWH showing that SO is present in 11–12% of enrolled MLWH regardless of the definition used. However, deep differences emerged using two different diagnostic definitions.
Literature
1.
2.
Brothers TD, Kirkland S, Guaraldi G, Falutz J, Theou O, Johnston BL, Rockwood K (2014) Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis 210(8):1170–1179PubMedCrossRef
3.
Frank Tahvi D et al (2019) Global, regional, and national incidence, prevalence, and mortality of HIV,1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the global burden of diseases 2017. Injuries, and Risk Factors Study Lancet HIV 6(12):e831–e859
4.
Taramasso L, Andreoni M, Antinori A, Bandera A, Bonfanti P, Bonora S, Borderi M, Castagna A, Cattelan AM, Celesia BM, Cicalini S, Cingolani A, Cossarizza A, D’Arminio Monforte A, D’Ettorre G, Di Biagio A, Di Giambenedetto S, Di Perri G, Esposito V, Focà E, Gervasoni C, Gori A, Gianotti N, Guaraldi G, Gulminetti R, Lo Caputo S, Madeddu G, Maggi P, Marandola G, Marchetti GC, Mastroianni CM, Mussini C, Perno CF, Rizzardini G, Rusconi S, Santoro M, Sarmati L, Zazzi M, Maggiolo F (2023) Pillars of long-term antiretroviral therapy success. Pharmacol Res 196:106898PubMedCrossRef
5.
Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F (2011) Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 53(11):1120–1126PubMedCrossRef
6.
Brothers TD, Rockwood K (2014) Biologic aging, frailty, and age-related disease in chronic HIV infection. Curr Opin HIV AIDS 9(4):412–418PubMedCrossRef
7.
Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazzi C, Carli F, Carani C, Guaraldi G (2011) Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS ONE 6(12):e28512PubMedPubMedCentralCrossRef
8.
Rochira V, Guaraldi G (2014) Hypogonadism in the HIV-infected man. Endocrinol Metab Clin North Am 43(3):709–730PubMedCrossRef
9.
Maffezzoni F, Porcelli T, Delbarba A, Pezzaioli LC, Properzi M, Cappelli C, Castelli F, Quiros-Roldan ME, Ferlin A (2020) Hypogonadism and bone health in men with HIV. Lancet HIV 7(11):e782–e790PubMedCrossRef
10.
11.
Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S (2018) Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int 29(3):595–613PubMedCrossRef
12.
13.
14.
Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, Hirsch SC, Linker A, Perros N, Servais AB, Taylor AP, Webb ML, Youngner JM, Yu EW (2016) Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest 126(3):1114–1125PubMedPubMedCentralCrossRef
15.
Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ (2013) Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 369(11):1011–1022PubMedPubMedCentralCrossRef
16.
Isidori AM, Aversa A, Calogero A, Ferlin A, Francavilla S, Lanfranco F, Pivonello R, Rochira V, Corona G, Maggi M (2022) Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE). J Endocrinol Invest 45(12):2385–2403PubMedPubMedCentralCrossRef
17.
Rochira V, Carani C (2023) Estrogens, 2000 Male Reproduction and Beyond. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000–2023, MDText.com, Inc.; 2000 10 56-78
18.
Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, Brown TT, Capeau J (2020) HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers 6(1):48PubMedCrossRef
19.
Dos-Santos-Quaresma MVL, Lima-Ribeiro SM (2022) Sarcopenia in persons living with HIV under antiretroviral therapy: literature review. AIDS Rev 24(1):1–15PubMed
20.
Guimarães NS, Raposo MA, Greco D, Tupinambás U, Premaor MO (2022) People living with hiv, lean mass, and sarcopenia: a systematic review and meta-analysis. J Clin Densitom 25(1):113–123PubMedCrossRef
21.
Wannamethee SG, Atkins JL (2015) Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc 74(4):405–412PubMedCrossRef
22.
Milic J, Calza S, Cantergiani S, Albertini M, Gallerani A, Menozzi M, Barp N, Todisco V, Renzetti S, Motta F, Mussini C, Sebastiani G, Raggi P, Guaraldi G (2023) Sarcopenic obesity phenotypes in patients with HIV: implications for cardiovascular prevention and rehabilitation. Can J Cardiol
23.
Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, Bauer JM, Boirie Y, Cruz-Jentoft AJ, Dicker D, Frara S, Frühbeck G, Genton L, Gepner Y, Giustina A, Gonzalez MC, Han HS, Heymsfield SB, Higashiguchi T, Laviano A, Lenzi A, Nyulasi I, Parrinello E, Poggiogalle E, Prado CM, Salvador J, Rolland Y, Santini F, Serlie MJ, Shi H, Sieber CC, Siervo M, Vettor R, Villareal DT, Volkert D, Yu J, Zamboni M, Barazzoni R (2022) Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin Nutr 41(4):990–1000PubMedCrossRef
24.
Gortan Cappellari G, Guillet C, Poggiogalle E, Ballesteros Pomar MD, Batsis JA, Boirie Y, Breton I, Frara S, Genton L, Gepner Y, Gonzalez MC, Heymsfield SB, Kiesswetter E, Laviano A, Prado CM, Santini F, Serlie MJ, Siervo M, Villareal DT, Volkert D, Voortman T, Weijs PJ, Zamboni M, Bischoff SC, Busetto L, Cederholm T, Barazzoni R, Donini LM (2023) Sarcopenic obesity research perspectives outlined by the sarcopenic obesity global leadership initiative (SOGLI) - Proceedings from the SOGLI consortium meeting in rome November 2022. Clin Nutr 42(5):687–699PubMedCrossRef
25.
De Vincentis S, Decaroli MC, Fanelli F, Diazzi C, Mezzullo M, Morini F, Bertani D, Milic J, Carli F, Cuomo G, Santi D, Tartaro G, Tagliavini S, De Santis MC, Roli L, Trenti T, Pagotto U, Guaraldi G, Rochira V (2021) Health status is related to testosterone, estrone and body fat: moving to functional hypogonadism in adult men with HIV. Eur J Endocrinol 184(1):107–122PubMedCrossRef
26.
Verschueren S, Gielen E, O’Neill TW, Pye SR, Adams JE, Ward KA, Wu FC, Szulc P, Laurent M, Claessens F, Vanderschueren D, Boonen S (2013) Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men. Osteoporos Int 24(1):87–98PubMedCrossRef
27.
Erlandson KM, Ng DK, Jacobson LP, Margolick JB, Dobs AS, Palella FJ Jr, Lake JE, Bui H, Kingsley L, Brown TT (2017) Inflammation, immune activation, immunosenescence, and hormonal biomarkers in the frailty-related phenotype of men with or at risk for HIV infection. J Infect Dis 215(2):228–237PubMed
28.
Rochira V, Diazzi C, Santi D, Brigante G, Ansaloni A, Decaroli MC, De Vincentis S, Stentarelli C, Zona S, Guaraldi G (2015) Low testosterone is associated with poor health status in men with human immunodeficiency virus infection: a retrospective study. Andrology 3(2):298–308PubMedCrossRef
29.
Hsu B, Cumming RG, Handelsman DJ (2018) Testosterone, frailty and physical function in older men. Expert Rev Endocrinol Metab 13(3):159–165PubMedCrossRef
30.
Hyde Z, Flicker L, Almeida OP, Hankey GJ, McCaul KA, Chubb SA, Yeap BB (2010) Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab 95(7):3165–3172PubMedCrossRef
31.
Travison TG, Shackelton R, Araujo AB, Hall SA, Williams RE, Clark RV, O’Donnell AB, McKinlay JB (2008) The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc 56(5):831–839PubMedPubMedCentralCrossRef
32.
Rastrelli G, Corona G, Maggi M (2020) Both comorbidity burden and low testosterone can explain symptoms and signs of testosterone deficiency in men consulting for sexual dysfunction. Asian J Androl 22(3):265–273PubMedCrossRef
33.
Park YW, Heymsfield SB, Gallagher D (2002) Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass? Int J Obes Relat Metab Disord 26(7):978–983PubMedCrossRef
34.
Shepherd JA, Schousboe JT, Broy SB, Engelke K, Leslie WD (2015) Executive summary of the ISCD position development conference on advanced measures from DXA and QCT fracture prediction beyond BMD. J Clin Densitom 18(3):274–286PubMedCrossRef
35.
Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147(8):755–763PubMedCrossRef
36.
Poggiogalle E, Lubrano C, Sergi G, Coin A, Gnessi L, Mariani S, Lenzi A, Donini LM (2016) Sarcopenic obesity and metabolic syndrome in adult caucasian subjects. J Nutr Health Aging 20(9):958–963PubMedCrossRef
37.
Oliveira VHF, Borsari AL, Webel AR, Erlandson KM, Deminice R (2020) Sarcopenia in people living with the human immunodeficiency virus: a systematic review and meta-analysis. Eur J Clin Nutr 74(7):1009–1021PubMedCrossRef
38.
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser (2000),894:1–253
39.
Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y (2000) Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 72(3):694–701PubMedCrossRef
40.
Fanelli F, Belluomo I, Di Lallo VD, Cuomo G, De Iasio R, Baccini M, Casadio E, Casetta B, Vicennati V, Gambineri A, Grossi G, Pasquali R, Pagotto U (2011) Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults. Steroids 76(3):244–253PubMedCrossRef
41.
Mezzullo M, Pelusi C, Fazzini A, Repaci A, Di Dalmazi G, Gambineri A, Pagotto U, Fanelli F (2020) Female and male serum reference intervals for challenging sex and precursor steroids by liquid chromatography - tandem mass spectrometry. J Steroid Biochem Mol Biol 197:105538PubMedCrossRef
42.
Büttler RM, Martens F, Fanelli F, Pham HT, Kushnir MM, Janssen MJ, Owen L, Taylor AE, Soeborg T, Blankenstein MA, Heijboer AC (2015) Comparison of 7 Published LC-MS/MS methods for the simultaneous measurement of testosterone, androstenedione, and dehydroepiandrosterone in serum. Clin Chem 61(12):1475–1483PubMedCrossRef
43.
Keevil BG, Adaway J (2019) Assessment of free testosterone concentration. J Steroid Biochem Mol Biol 190:207–211PubMedCrossRef
44.
Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84(10):3666–3672PubMedCrossRef
45.
Guaraldi G, Brothers TD, Zona S, Stentarelli C, Carli F, Malagoli A, Santoro A, Menozzi M, Mussi C, Mussini C, Kirkland S, Falutz J, Rockwood K (2015) A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS 29(13):1633–1641PubMedCrossRef
46.
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16–31PubMedCrossRef
47.
Buehring B, Kirchner E, Sun Z, Calabrese L (2012) The frequency of low muscle mass and its overlap with low bone mineral density and lipodystrophy in individuals with HIV–a pilot study using DXA total body composition analysis. J Clin Densitom 15(2):224–232PubMedCrossRef
48.
Dutta D, Sharma M, Bansal R, Sharma N, Garga UC, Anand A, Gaurav K (2017) Low skeletal mass is an important predictor of osteoporosis in HIV-infected men in India. Endokrynol Pol 68(6):642–651PubMed
49.
Hawkins KL, Zhang L, Ng DK, Althoff KN, Palella FJ Jr, Kingsley LA, Jacobson LP, Margolick JB, Lake JE, Brown TT, Erlandson KM (2018) Abdominal obesity, sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV. AIDS 32(10):1257–1266PubMedCrossRef
50.
Mialich MS, Dos Santos AP, da Silva BR, de Paula FJ, Jordão AA, Navarro AM (2017) Relationship between adiposity indices, lipodystrophy, and sarcopenia in HIV-positive individuals with and without lipodystrophy. J Clin Densitom 20(1):73–81PubMedCrossRef
51.
Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB (2013) Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr 63(2):209–215PubMedPubMedCentralCrossRef
52.
Echeverría P, Bonjoch A, Puig J, Estany C, Ornelas A, Clotet B, Negredo E (2018) High prevalence of sarcopenia in HIV-infected individuals. Biomed Res Int 2018:5074923PubMedPubMedCentralCrossRef
53.
Gregson CL, Madanhire T, Rehman A, Ferrand RA, Cappola AR, Tollman S, Mokoena T, Micklesfield LK, Wade AN, Fabian J (2022) Osteoporosis, rather than sarcopenia, is the predominant musculoskeletal disease in a rural south african community where human immunodeficiency virus prevalence is high: a cross-sectional study. J Bone Miner Res 37(2):244–255PubMedCrossRef
54.
Oliveira VHF, Borsari AL, Cárdenas JDG, Alves Junior CM, Castro NF, Marinello PC, Padilha CS, Webel AR, Erlandson KM, Deminice R (2021) Low agreement between initial and revised european consensus on definition and diagnosis of sarcopenia applied to people living with HIV. J Acquir Immune Defic Syndr 86(4):e106–e113PubMedCrossRef
55.
Liu P, Hao Q, Hai S, Wang H, Cao L, Dong B (2017) Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: a systematic review and meta-analysis. Maturitas 103:16–22PubMedCrossRef
56.
Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, Bacchetti P, Shlipak MG, Grunfeld C (2011) Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 25(11):1405–1414PubMedCrossRef
57.
Sousa AS, Guerra RS, Fonseca I, Pichel F, Ferreira S, Amaral TF (2016) Financial impact of sarcopenia on hospitalization costs. Eur J Clin Nutr 70(9):1046–1051PubMedCrossRef
58.
Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA (2018) Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103(5):1715–1744PubMedCrossRef
59.
Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63(3):280–293PubMedCrossRef
60.
Konishi K, Nakagawa H, Asaoka T, Kasamatsu Y, Goto T, Shirano M (2022) Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition. Medicine (Baltimore) 101(42):e31349PubMedCrossRef
61.
Batsis JA, Villareal DT (2018) Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 14(9):513–537PubMedPubMedCentralCrossRef
62.
Roh E, Choi KM (2020) Health consequences of sarcopenic obesity: a narrative review. Front Endocrinol (Lausanne) 11:332PubMedCrossRef
63.
Santi D, Madeo B, Carli F, Zona S, Brigante G, Vescini F, Guaraldi G, Rochira V (2016) Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study. Osteoporos Int 27(3):1103–1114PubMedCrossRef
64.
Abreu JM, Nogueira ABB, Villela MM, Módolo DM, Panaro TC, Setubal S, Velarde LGC, Lima GAB, da Cruz Filho RA, Soares DV (2022) Low bone mass and vitamin D in Brazilian people living with HIV under antiretroviral therapy. Arch Osteoporos 17(1):40PubMedCrossRef
65.
Qin H, Jiao W (2022) Correlation of muscle mass and bone mineral density in the NHANES US general population, 2017–2018. Medicine (Baltimore) 101(39):e30735PubMedCrossRef
66.
Hirschfeld HP, Kinsella R, Duque G (2017) Osteosarcopenia: where bone, muscle, and fat collide. Osteoporos Int 28(10):2781–2790PubMedCrossRef
67.
Rochira V, Antonio L, Vanderschueren D (2018) EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology 6(2):272–285PubMedCrossRef
68.
Wasserman P, Segal-Maurer S, Rubin DS (2014) High prevalence of low skeletal muscle mass associated with male gender in midlife and older HIV-infected persons despite CD4 cell reconstitution and viral suppression. J Int Assoc Provid AIDS Care 13(2):145–152PubMedCrossRef
69.
Yarasheski KE, Scherzer R, Kotler DP, Dobs AS, Tien PC, Lewis CE, Kronmal RA, Heymsfield SB, Bacchetti P, Grunfeld C (2011) Age-related skeletal muscle decline is similar in HIV-infected and uninfected individuals. J Gerontol A Biol Sci Med Sci 66(3):332–340PubMedCrossRef
70.
Oliveira VH, Wiechmann SL, Narciso AM, Webel AR, Deminice R (2018) Muscle strength is impaired in men but not in women living with HIV taking antiretroviral therapy. Antivir Ther 23(1):11–19PubMedCrossRef
71.
Banica T, Verroken C, Reyns T, T’Sjoen G, Fiers T, Kaufman JM, Lapauw B (2023) Physiological declines in sex steroid exposure in relation to changes in body composition in healthy men-a prospective cohort study. Eur J Endocrinol 188(6):510–518PubMedCrossRef
72.
Vandenput L, Mellström D, Karlsson MK, Orwoll E, Labrie F, Ljunggren O, Ohlsson C (2010) Serum estradiol is associated with lean mass in elderly Swedish men. Eur J Endocrinol 162(4):737–745PubMedCrossRef
73.
Gielen E, O’Neill TW, Pye SR, Adams JE, Wu FC, Laurent MR, Claessens F, Ward KA, Boonen S, Bouillon R, Vanderschueren D, Verschueren S (2015) Endocrine determinants of incident sarcopenia in middle-aged and elderly European men. J Cachexia Sarcopenia Muscle 6(3):242–252PubMedPubMedCentralCrossRef
74.
75.
Martin J, Volberding P (2010) A field still in its infancy. Ann Intern Med. United States HIV and premature aging 153:477–479
76.
Rochira V (2017) Hypogonadism in systemic diseases. In: Simoni M, Huhtaniemi I (eds) Endocrinology of the testis and male reproduction. Springer International Publishing, Cham, pp 1–51
77.
Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, Vanderschueren D, Wu FC (2020) European academy of andrology (EAA) guidelines* on investigation, treatment and monitoring of functional hypogonadism in males. Andrology 2020(10):34–56
Metadata
Title
Sarcopenic obesity and reduced BMD in young men living with HIV: body composition and sex steroids interplay
Authors
S. De Vincentis
C. Greco
F. Fanelli
M. C. Decaroli
C. Diazzi
M. Mezzullo
J. Milic
M. C. De Santis
L. Roli
U. Pagotto
G. Guaraldi
V. Rochira
Publication date
20-04-2024
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-024-02375-6

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits